Factores asociados a la enfermedad arterial periférica en pacientes con diabetes mellitus tipo 2 en una población de un Centro Médico del Oriente Colombiano

dc.contributor.advisorWandurraga Sánchez, Edwin Antonio
dc.contributor.advisorOchoa Vera, Miguel Enrique
dc.contributor.authorMayorga Quintero, Jairo Alberto
dc.contributor.cvlacWandurraga Sánchez, Edwin Antonio [0001475567]spa
dc.contributor.cvlacOchoa Vera, Miguel Enrique [0000898465]spa
dc.contributor.orcidWandurraga Sánchez, Edwin Antonio [0000-0002-0529-2343]spa
dc.contributor.orcidOchoa Vera, Miguel Enrique [0000-0002-4552-3388]spa
dc.contributor.researchgateWandurraga Sánchez, Edwin Antonio [Edwin-Antonio-Wandurraga-Sanchez-2213883366]spa
dc.contributor.researchgateOchoa Vera, Miguel Enrique [Miguel-Ochoa-6]spa
dc.contributor.researchgroupObservatorio de Salud Pública de Santanderspa
dc.contributor.researchgroupGrupo de Investigaciones Clínicasspa
dc.coverage.campusUNAB Campus Bucaramangaspa
dc.coverage.spatialBucaramanga (Santander, Colombia)spa
dc.coverage.temporal2021spa
dc.date.accessioned2022-03-25T19:39:21Z
dc.date.available2022-03-25T19:39:21Z
dc.date.issued2022
dc.degree.nameEspecialista en Medicina Internaspa
dc.description.abstractIntroducción: La enfermedad arterial periférica (EAP) en pacientes con diabetes mellitus tipo 2 (DM2) conlleva a un mayor riesgo de morbimortalidad cardiovascular, complicaciones locales (amputaciones) y deterioro funcional. Conocer los factores asociados a la presencia de EAP en dicha población permitirá optimizar estrategias de prevención, diagnóstico y tratamiento para disminuir el impacto negativo de esta asociación. Materiales y métodos: Se condujo un estudio transversal analítico. Fueron elegibles los pacientes con DM2 participando en un estudio clínico, además de casos detectados consecutivamente (Junio - Septiembre de 2021) en la clínica FOSCAL. Identificando la presencia de EAP (Historia clínica y/o indice tobillo brazo), se describieron las características sociodemográficas, clínicas y los factores de riesgo cardiovascular convencionales. Se calculó la prevalencia de EAP y se adelantó análisis bivariado para explorar la asociación de las variables explicatorias con la presencia de EAP, calculando razones de prevalencia y sus intervalos de confianza del 95%. Resultados: Muestra de 202 pacientes, 55,5% hombres, edad promedio de 64,6 años. Se estableció una prevalencia de EAP del 30,6%, el 28,8% tenían historia de amputación, 27,1% Fontaine IV, 15,3% Fontaine III. Las variables asociadas a la EAP fueron la edad, el tiempo de evolución de la DM2, HTA, cardiopatía isquémica, enfermedad cerebrovascular, fibrilación auricular, enfermedad renal crónica, hemodialisis, sedentarismo, extabaquismo, mediana de LDL, triglicerios, albuminuria A2 y A3 . Conclusiones: En los pacientes con DM2 de la población en estudio hay una alta prevalencia de EAP y se presenta predominante en formas más severas. Se deben enfocar los esfuerzos en los pacientes que presentan los factores asociados mencionados y en los factores de riesgo tradicionales, para optimizar las estrategias de diagnóstico oportuno y tratamiento adecuado en base a las guías de práctica clínica, con el objetivo de disminuir el impacto de la EAP en cuanto a complicaciones de las extremidades, funcionalidad y morbimortalidad cardiovascular.spa
dc.description.abstractenglishIntroduction: The Peripheral arterial disease (PAD) in patients with type 2 diabetes mellitus (T2DM) carries a higher risk of cardiovascular morbidity and mortality, local complications (amputations) and functional impairment. Identify the factors associated with the presence of PAD in this population will allow to optimize of prevention, diagnosis and treatment strategies to reduce the negative impact of these associations. Materials and methods: An analytical cross-sectional study was conducted. Patients with DM2 including in a clinical study were eligible, in addition to cases detected consecutively (June - September 2021) at the FOSCAL clinic. Identifying the presence of PAD (medical history and/or ankle-brachial index), the sociodemographic and clinical characteristics and conventional cardiovascular risk factors were described. The prevalence of PAD was calculated and a bivariate analysis was carried out to explore the association of the explanatory variables with the presence of PAD, calculating prevalence ratios and their 95% confidence intervals. Results: A sample of 202 patients, 55.5% men, average age: 64.6 years. A prevalence of PAD of 30.6% was established, 28.8% had a history of amputation, 27.1% Fontaine IV, 15.3% Fontaine III. The variables associated with PAD were age, time since T2DM, hypertension, ischemic heart disease, cerebrovascular disease, atrial fibrillation, chronic kidney disease, hemodialysis, sedentary lifestyle, former smoker, median LDL, triglycerides, A2 and A3 albuminuria. Conclusions: In patients with T2DM in our population there is a high prevalence of PAD and it occurs predominantly in more severe forms. Efforts should be focused on patients who present the aforementioned associated factors and traditional risk factors, to optimize strategies for timely diagnosis and adequate treatment based on clinical practice guidelines, with the aim of reducing the impact of the disease. PAD in terms of limb complications, functionality and cardiovascular morbidity and mortality.spa
dc.description.degreelevelEspecializaciónspa
dc.description.learningmodalityModalidad Presencialspa
dc.description.tableofcontentsResumen ……………………………………………………………………………….………….…….10 Planteamiento y justificación del problema ……………………………...……………………...……14 Marco teórico ………………………………………………………………………………...………….16 Enfermedad arterial periférica …………………………………….……………….………….16 Definición y clasificación …….………………………….………………………….………….16 Epidemiología …………………………………………………..............………….………….16 Fisiopatología ………………………………………….……………………………………….17 Evaluación clínica ………………………………………….……………………………….….16 Pruebas diagnósticas ………………………………………………….……………………… 22 Tratamiento …………………………………………..…………………………………..….… 24 Disminución del colesterol ………………………………….…………………......… 24 Agentes antiplaquetarios ………………………………….…….…………………... 26 Anticoagulación ………………………………..……….………………………....…. 27 Vasodilatadores periféricos ………………………………….………………….….. 27 Control glicémicos ………………………………………………………….…….….. 28 Agentes antihipertensivos ………………………………….………………...….….. 29 Dejar de fumar ………………………………………………...………………….….. 30 Revascularización quirúrgica o endovascular …………………………………….. 31 Terapia con células madre ………………………..……………………….…….…. 32 Estado del arte ………………………………….…….…………………………………………... 33 Objetivos …………………………..…………….…….…………………………………………... 35 Objetivo general ………….…………………….…….…………………………….……………... 35 Objetivos específicos …………………………………...………………………………………... 35 Metodología ………………………………….…….……………………………….……………... 35 Tipo de estudio ………………...……………….…….…………….…….…………...……... 35 Población ……………………………..…….…….…….…….…………..…………………... 36 Criterios de inclusión y exclusión ……..………………….…….…………..…….…….…... 36 Recolección de la información ……….………………………….….……..……..….……... 36 Tamaño de muestra ……………………….…….…………………………….……………... 37 Muestreo ……………………..……………………….…….…………..…………………...... 37 Variables ……………………..…….…….……………………………….…….……...……... 37 Plan de análisis de datos ……………………..…….….…….…………..….…….…..……. 37 Consideraciones éticas …………….…….………….………..…….…….………………..…..... 38 Resultados ……………………..…….…….……………………………………….………..….... 40 Análisis descriptivo ……………………..…….…….………………………….……….….... 40 Descripción general de la población ……………..………..…….………………….…….... 40 Prevalencia, manifestaciones clínicas y severidad de la EAP …….…………...……...... 42 Descripción general de los pacientes con EAP ……………..……………….………..…. 45 Análisis bivariado ……..…………………..…….……………………..….….……..…..…... 46 Discusión …………………………………………………………………………….……….……. 55 Conclusiones ……………………………………..………………………………………….……. 63 Referencias bibliográficas ………………………………………………………………….……. 65 Anexos ………………………………………………………72spa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga - UNABspa
dc.identifier.reponamereponame:Repositorio Institucional UNABspa
dc.identifier.repourlrepourl:https://repository.unab.edu.cospa
dc.identifier.urihttp://hdl.handle.net/20.500.12749/16063
dc.language.isospaspa
dc.publisher.facultyFacultad Ciencias de la Saludspa
dc.publisher.grantorUniversidad Autónoma de Bucaramanga UNABspa
dc.publisher.programEspecialización en Medicina Internaspa
dc.relation.references1. International Diabetes Federation. IDF Diabetes Atlas Eighth Edition 2017 [Internet]. [Consultado 3 Julio 2020]. Disponible en: https://www.idf.org/e-library/epidemiology research/diabetes-atlas/134-idf-diabetes-atlas-8th-edition.spa
dc.relation.references2. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843spa
dc.relation.references3. Alvernia MJ, García M, CamachoPA , Uribe S, Pérez M, López P. Determinantes de la prevalencia de prediabetes y diabetes mellitus tipo 2 en Colombia: estudio PURE. Revista Colombiana de Endocrinología, Diabetes y Metabolismo. 2019; 6(1):67-68.spa
dc.relation.references4. A. Rawshani, A. Rawshani, S. Franzen, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376(15):1407-1418.spa
dc.relation.references5. M.H. Criqui, V. Aboyans. Epidemiology of peripheral artery disease. Circ Res, 2015; 116(9):1509-26spa
dc.relation.references6. Song P, Rudan D, Zhu Y, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019;7(8): 1020–1030spa
dc.relation.references7. Low Wang CC , Blomster JI , Heizer G , et al. Resultados cardiovasculares y de extremidades en pacientes con diabetes y enfermedad arterial periférica: el ensayo EUCLID . J Am Coll Cardiol. 2018 ; 72 (25): 3274 - 3284spa
dc.relation.references8. Stefanos Giannopoulos, Ehrin J. Armstrong. Diabetes mellitus: an important risk factor for peripheral vascular disease. Expert Rev Cardiovasc Ther. 2020;18(3):131-13spa
dc.relation.references9. Shahab Hajibandeh, Shahin Hajibandeh, Sohan Shah, et al. Prognostic significance of ankle brachial pressure index: A systematic review and meta-analysis. Vascular. 2017;25(2):208-224.spa
dc.relation.references10. Secretaría de salud de Santander, observatorio de salud pública de Santander. Factores de riesgo para enfermedades crónicas en Santander, método STEPwise [Internet]. [Consultado 3 Jul 2020]. Disponible en: https://www.who.int/ncds/surveillance/steps/2010_STEPS_Survey_Colombia.pdfspa
dc.relation.references11. Fondo colombiando de enfermedades de alto costo. Situación de la enfermedad renal crónica, la hipertensión arterial y la diabetes mellitus en Colombia – 2018. [Internet]. [Consultado 3 Jul 2020]. Disponible en: https://cuentadealtocosto.org/site/erc/.spa
dc.relation.references12. Nativel M, Potier L, Alexandre L, et al. Lower extremity arterial disease in patients with diabetes: a contemporary narrative review. Cardiovasc Diabetol. 2018;17:138.spa
dc.relation.references13. Graham H. Bevan, Khendi T. White Solaru. Evidence Based Medical Management of Peripheral Artery Disease. Arterioscler Thromb Vasc Biol. 2020;40(3):541-553spa
dc.relation.references14. Fowkes FGR Rudan D Rudan I et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013; 382: 1329-1340.spa
dc.relation.references15. Lorena Urbanoa, Eliana Portilla, Wilson Muñoz, et al. Prevalence and risk factors associated with peripheral arterial disease in an adult population from Colombia. Arch Cardiol Mex. Apr-Jun 2018;88(2):107-115.spa
dc.relation.references16. Carolina Guzmán, Juan Camilo Marulanda, John Fernando García, et al. Perfil epidemiológico de pacientes con enfermedad arterial periférica afiliados a una EPS en Colombia en el año 2016. 2016. Disponible en: https://repository.ces.edu.co/bitstream/10946/3502/1/Perfil%20Epidemiologico%20Paciente%20 Enfermedad%20Arterial.pdfspa
dc.relation.references17. Smriti Murali Krishna, Joseph V. Moxon, Jonathan Golledge et al. A Review of the Pathophysiology and Potential Biomarkers for Peripheral Artery Disease. Int J Mol Sci. 2015;16(5):11294–11322.spa
dc.relation.references18. Thejasvi Thiruvoipati, Caitlin E Kielhorn, Ehrin J Armstrong. Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes. World J Diabetes. 2015;6(7):961–969.spa
dc.relation.references19. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726–e779spa
dc.relation.references20. Halliday A, Bax JJ. The 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS) Eur J Vasc Endovasc Surg. 2018;55(3):301–302.spa
dc.relation.references21. Jonathon M Firnhaber, C S Powell. Lower Extremity Peripheral Artery Disease: Diagnosis and Treatment. Am Fam Physician. 2019; 15;99(6):362-369.spa
dc.relation.references22. Guirguis-Blake JM, Evans CV, Redmond N, Lin JS. Screening for peripheral artery disease using the ankle-brachial index: updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;320:184–196spa
dc.relation.references23. Graham H. Bevan, Khendi T. White Solaru. Evidence Based Medical Management of Peripheral Artery Disease. Arterioscler Thromb Vasc Biol. 2020;40(3):541-553spa
dc.relation.references24. Grundy, SM, Stone, NJ, Bailey, AL, Beam, C, Birtcher, KK, Blumenthal, RS, Braun, LT, de Ferranti, S, Faiella-Tommasino, J, Forman, DE, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73:e285–e350.spa
dc.relation.references25. Arya, S, Khakharia, A, Binney, ZO, DeMartino, RR, Brewster, LP, Goodney, PP, Wilson, PWF. Association of statin dose with amputation and survival in patients with peripheral artery disease. Circulation. 2018;137:1435–1446spa
dc.relation.references26. Sonia S Anand, Francois Caron, John W Eikelboom, et al. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. J Am Coll Cardiol. 2018;71(20):2306-2315spa
dc.relation.references27. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15I):1577–89.spa
dc.relation.references28. Jonathon M. Firnhaber. Lower Extremity Peripheral Artery Disease: Diagnosis and Treatment. American Family Physician. 2019;99(6): 362-36spa
dc.relation.references29. Rigato M, Monami M, Fadini GP. Autologous cell therapy for peripheral arterial disease: systematic review and meta-analysis of randomized, nonrandomized, and noncontrolled studies. Circ Res. 2017;120(8I):1326–40.spa
dc.relation.references30. Amanda I Adler, Richard J Stevens, Andrew Neil, et al. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care. 2002;25(5):894-9.spa
dc.relation.references31. Kamel Mohammedi, Mark Woodward, Yoichiro Hirakawa, et al. Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes. Diabetes Care. 2016;39(10):1796-spa
dc.relation.references32. Andrew D Althouse, J Dawn Abbott, Alan D Forker, et al. Risk factors for incident peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation in type 2 Diabetes (BARI 2D) Trial. Diabetes Care. 2014;37(5):1346-52spa
dc.relation.references33. J.L.Montero-Monterrosoa, J.A.Gascón-Jiméneza, Vargas-Rubio, et al. Prevalencia y factores asociados a la enfermedad arterial periférica en pacientes con diabetes mellitus tipo 2 en Atención Primaria. Semergen.2015;41(4):183-190.spa
dc.relation.references34. Ikem R, Ikem I, Adebayo O, Soyoye D. An assessment of peripheral vascular disease in patients with diabetic foot ulcer. Foot (Edinb) 2010;20:114–117.spa
dc.relation.references36. Escobar Oliva B, García Castillo O, Redondo M. Enfermedad arterial periférica. AMF 2014; 10(9): 484-493.spa
dc.relation.references37. M. Mostaza, C. Suarez, L. Manzano, M. Cairols, F. Lopez-Fernandez, I. Aguilar, Merito Study Group, et al. Sub-clinical vascular disease in type 2 diabetic subjects: Relationship with chronic complications of diabetes and the presence of cardiovascular disease risk factors. Eur J Intern Med, 19 (2008), pp. 255-260.spa
dc.relation.references38. J. Mancera Romero, F. Paniagua Gómez, I. Martos Cerezuela, A. Baca Osorio, S. Ruiz Vera, P. González Santos, et al. Enfermedad arterial periférica oculta en población diabética seguida en atención primaria. Clin Invest Arterioscl, 22 (2010), pp. 154-16spa
dc.relation.references39. I. Vicente, C. Lahoz, M. Taboada, F. Laguna, F. Garcia-Iglesias, J.M. Mostaza Prieto. Índice tobillo-brazo en pacientes con diabetes mellitus: prevalencia y factores de riesgo. Rev Clin Esp, 206 (2006), pp. 225-229.spa
dc.relation.references40. Suominen V, Rantanen T, Venermo M, Saarinen J, Salenius J. Prevalence and risk factors of PAD among patients with elevated ABI. Eur J Vasc Endovasc Surg. 2008 Jun;35(6):709-14spa
dc.relation.references41. Cardoso CRL, Melo JV, Santos TRM, Leite NC, Salles GF. Traditional and non-traditional risk factors for peripheral artery disease development/progression in patients with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study. Cardiovasc Diabetol. 2021 Feb 27;20(1):54spa
dc.relation.references42. Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, Howard BV. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation. 2004 Feb 17;109(6):733-9.spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.rights.localAbierto (Texto Completo)spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.subject.keywordsInternal medicinespa
dc.subject.keywordsMedicinespa
dc.subject.keywordsMedical sciencesspa
dc.subject.keywordsHealth sciencesspa
dc.subject.keywordsPeripheral arterial disease (PAD)spa
dc.subject.keywordsType 2 diabetes mellitus (T2DM)spa
dc.subject.keywordsMetabolism disordersspa
dc.subject.keywordsDiseases of the endocrine glandsspa
dc.subject.keywordsArteriesspa
dc.subject.keywordsCardiovascular systemspa
dc.subject.lembMedicina internaspa
dc.subject.lembMedicinaspa
dc.subject.lembCiencias médicasspa
dc.subject.lembTrastornos del metabolismospa
dc.subject.lembEnfermedades de las glándulas endocrinasspa
dc.subject.lembArteriasspa
dc.subject.lembSistema cardiovascularspa
dc.subject.proposalCiencias de la saludspa
dc.subject.proposalEnfermedad arterial periférica (EAP)spa
dc.subject.proposalDiabetes mellitus tipo 2 (DM2)spa
dc.titleFactores asociados a la enfermedad arterial periférica en pacientes con diabetes mellitus tipo 2 en una población de un Centro Médico del Oriente Colombianospa
dc.title.translatedFactors associated with peripheral arterial disease in patients with diabetes type 2 mellitus in a population of a Medical Center of the Colombian Eastspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdcc
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.type.localTesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TM

Archivos

Bloque original

Mostrando 1 - 2 de 2
Cargando...
Miniatura
Nombre:
2022_Tesis_Jairo_Alberto_Mayorga.pdf
Tamaño:
1.14 MB
Formato:
Adobe Portable Document Format
Descripción:
Tesis
Cargando...
Miniatura
Nombre:
2022_Licencia_Jairo_Alberto_Mayorga.pdf
Tamaño:
3.14 MB
Formato:
Adobe Portable Document Format
Descripción:
Licencia

Bloque de licencias

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
license.txt
Tamaño:
829 B
Formato:
Item-specific license agreed upon to submission
Descripción: